G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts

Author(s): Claus Liebmann

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 16 , 2004

Become EABM
Become Reviewer
Call for Editor


In recent years, new strategies in cancer therapy have been developed targeting key signaling molecules in the receptor tyrosine kinase signal transduction pathway. In contrast, most therapeutical concepts to manipulate G protein-coupled receptors (GPCR)-mediated disorders are still limited to the use of receptor-specific agonists or antagonists. Visible progress in the understanding of GPCR signaling complexity, especially the detection of several families of highly target- and cell-specific regulator proteins of GPCRs, G proteins, and effector components may open new horizons to develop novel therapeutical concepts targeting GPCR signaling elements. Thus, this review will focus on different molecular levels that may be of particular interest in terms of new drug development such as: (i) GPCR subtypes, allosteric binding sites, dimerization and constitutive activity, the use of RAMPs (receptor-activity-modifying proteins) and RASSLs (receptor activated solely by synthetic ligands); (ii) AGS (activators of G protein signaling) and RGS (regulators of G protein signaling) proteins which modify G protein activity; (iii) the high diversity of isozymes involved in the generation, signal transmission, and degradation of second messenger molecules.

Keywords: g protein-coupled receptors, subtypes, signaling pathways, novel modifying proteins, Isozymes, targeted therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [1937 - 1958]
Pages: 22
DOI: 10.2174/1381612043384367
Price: $65

Article Metrics

PDF: 9